UBS Group
COCH icon

UBS Group’s Envoy Medical COCH Stock Holding History

UBS Group’s Portfolio COCH Stock Details COCH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.9K Buy
70,459
+45,041
+177% +$30.7K ﹤0.01% 7408
2025
Q4 		$16.8K Buy
25,418
+1,320
+5% +$1.04K ﹤0.01% 7904
2025
Q3 		$18.7K Buy
24,098
+10,032
+71% +$13.6K ﹤0.01% 8196
2025
Q2 		$20K Sell
14,066
-12,491
-47% -$18.3K ﹤0.01% 8440
2025
Q1 		$34.5K Buy
26,557
+17,272
+186% +$25.3K ﹤0.01% 7854
2024
Q4 		$13.3K Buy
+9,285
New +$21.1K ﹤0.01% 8148
2024
Q3 		– Sell
-6,042
Closed -$14.3K – 9561
2024
Q2 		$14.3K Buy
+6,042
New +$22.5K ﹤0.01% 7523
2023
Q1 		– Sell
-1,011
Closed -$10.1K – 9680
2022
Q4 		$10.1K Buy
1,011
+640
+173% +$6.37K ﹤0.01% 8566
2022
Q3 		$4K Sell
371
-577
-61% -$5.67K ﹤0.01% 9344
2022
Q2 		$9K Hold
948
– – ﹤0.01% 8122
2022
Q1 		$9K Buy
948
+20
+2% +$195 ﹤0.01% 8535
2021
Q4 		$9K Sell
928
-910
-50% -$8.88K ﹤0.01% 8890
2021
Q3 		$18K Buy
1,838
+437
+31% +$4.23K ﹤0.01% 7269
2021
Q2 		$14K Buy
+1,401
New +$13.6K ﹤0.01% 7699

Other funds holding COCH

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCA
DSG Capital Advisors Edina, Minnesota $704M AUM 34.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Focus Partners Wealth
Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return
ACP
Arcus Capital Partners Atlanta, Georgia $278M AUM 14.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
CBU
CIBC Bancorp USA Chicago, Illinois $74.4B AUM

UBS Group's COCH Position: Q1 2026 in Review

UBS Group increased its Envoy Medical (COCH) stake by 177% in Q1 2026, buying an estimated $30.7K and bringing the position to 70,459 shares worth $46.9K. The position accounts for ﹤0.01% of the portfolio, ranked #7408.

UBS Group first reported a position in COCH in Q2 2021 and has held it in 14 quarters since. 33 funds tracked by Wall St. Rank hold COCH as of Q1 2026.

  • UBS Group held 70,459 shares of Envoy Medical worth $46.9K as of Q1 2026.
  • UBS Group bought 45,041 Envoy Medical shares in Q1 2026, an estimated $30.7K.
  • Envoy Medical made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7408 holding.
  • UBS Group first reported a position in Envoy Medical in Q2 2021 and has held it in 14 quarters since.
  • 33 funds tracked by Wall St. Rank held Envoy Medical as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.